Enzyme Engineering Strategies for the Bioenhancement of <sc>l</sc>-Asparaginase Used as a Biopharmaceutical
| Primer Autor |
Zamorano, Mauricio
|
| Co-autores |
Miranda, Javiera
Lefin, Nicolas
Beltran, Jorge F.
Belen, Lisandra Herrera
Tsipa, Argyro
Farias, Jorge G.
|
| Título |
Enzyme Engineering Strategies for the Bioenhancement of <sc>l</sc>-Asparaginase Used as a Biopharmaceutical
|
| Editorial |
ADIS INT LTD
|
| Revista |
BIODRUGS
|
| Lenguaje |
en
|
| Resumen |
Over the past few years, there has been a surge in the industrial production of recombinant enzymes from microorganisms due to their catalytic characteristics being highly efficient, selective, and biocompatible. l-asparaginase (l-ASNase) is an enzyme belonging to the class of amidohydrolases that catalyzes the hydrolysis of l-asparagine into l-aspartic acid and ammonia. It has been widely investigated as a biologic agent for its antineoplastic properties in treating acute lymphoblastic leukemia. The demand for l-ASNase is mainly met by the production of recombinant type II l-ASNase from Escherichia coli and Erwinia chrysanthemi. However, the presence of immunogenic proteins in l-ASNase sourced from prokaryotes has been known to result in adverse reactions in patients undergoing treatment. As a result, efforts are being made to explore strategies that can help mitigate the immunogenicity of the drug. This review gives an overview of recent biotechnological breakthroughs in enzyme engineering techniques and technologies used to improve anti-leukemic l-ASNase, taking into account the pharmacological importance of l-ASNase.
|
| Fecha Publicación |
2023
|
| Tipo de Recurso |
artículo de revisión
|
| doi |
10.1007/s40259-023-00622-5
|
| Formato Recurso |
PDF
|
| Palabras Claves |
Antineoplastic Agents / therapeutic use
Asparaginase / therapeutic use
Biological Factors
Biological Products / therapeutic use
Escherichia coli / metabolism
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Protein Engineering / methods
|
| Ubicación del archivo | |
| Categoría OCDE |
Oncología
Inmunología
Farmacología y Farmacia
|
| Materias |
Agentes Antineoplásicos/uso terapéutico
Asparaginasa/uso terapéutico
Factores Biológicos
Productos Biológicos/uso terapéutico
Escherichia coli/metabolismo
Humanos
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia farmacológica
Ingeniería de proteínas / métodos
|
| Página de inicio (Recomendado-único) |
793.0
|
| Página final (Recomendado-único) |
811
|
| Identificador del recurso (Mandatado-único) |
artículo de revisión
|
| Versión del recurso (Recomendado-único) |
versión publicada
|
| Derechos de acceso |
metadata
|
| Access Rights |
metadata
|
| Id de Web of Science |
WOS:001067824200001
|
| ISSN |
1173-8804
|
| Categoría WOS |
Oncología
Inmunología
Farmacología y Farmacia
|
| Referencia del Financiador (Mandatado si es aplicable-repetible) |
FAPESP UFRO 2020/06982-3
|
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl